Roy-Chaudhury Prabir, Kelly Burnett S, Melhem Murad, Zhang Jianhua, Li Jinsong, Desai Pankaj, Munda Rino, Heffelfinger Sue C
Division of Nephrology and Hypertension, University of Cincinnati Medical Center, 231 Albert Sabin Way, Cincinnati, OH 45267, USA.
Cardiol Clin. 2005 Aug;23(3):249-73. doi: 10.1016/j.ccl.2005.04.004.
This article (1) identifies the types of hemodialysis access, (2) summarizes the clinical standard of care for dialysis access grafts and fistulae, (3) describes the pathology and pathogenesis of venous stenosis in dialysis access grafts and fistulae, (4) tabulates avail-able therapies for hemodialysis vascular access dysfunction and speculates on the rea-sons for the lack of effective therapies, and (5) discusses the development and application of novel therapeutic interventions for this difficult clinical problem. The possibility that dialysis access grafts and fistulae could be the ideal clinical model for testing novel local therapies to block neointimal hyperplasia is discussed.
本文（1）确定了血液透析通路的类型，（2）总结了透析通路移植物和动静脉内瘘的临床护理标准，（3）描述了透析通路移植物和动静脉内瘘静脉狭窄的病理及发病机制，（4）列出了血液透析血管通路功能障碍的可用治疗方法并推测缺乏有效治疗方法的原因，（5）讨论了针对这一棘手临床问题的新型治疗干预措施的开发与应用。文中还讨论了透析通路移植物和动静脉内瘘成为测试新型局部疗法以阻断内膜增生的理想临床模型的可能性。
